Uloric

Uloric is a brand name of febuxostat, approved by the FDA in the following formulation(s):

ULORIC (febuxostat - tablet; oral)

• 
  Manufacturer: TAKEDA PHARMS
  
  Approval date: February 13, 2009
  
  Strength(s): 40MG, 80MG ^[RLD]

Has a generic version of Uloric been approved?

No. There is currently no therapeutically equivalent version of Uloric available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Uloric. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  2-arylthiazole derivatives and pharmaceutical composition thereof
  Patent 5,614,520
  Issued: March 25, 1997
  Inventor(s): Kondo; Shiro & Fukushima; Hisashi & Hasegawa; Masaichi & Tsuchimoto; Masahiro & Nagata; Ikuo & Osada; Yoshio & Komoriya; Keiji & Yamaguchi; Hisao
  Assignee(s): Teijin Limited
  Pharmaceutical compositions for treating gout or hyperuricemia and containing a new categorized compound, i.e. 2-arylthiazole derivatives, as an active ingredient, are provided. The 2-arylthiazole derivatives in the present invention are represented by the following formula (I): ##STR1## wherein Ar is an unsubstituted or substituted pyridyl, thienyl, furyl, naphthyl or phenyl group; X is a hydrogen atom, alkyl group or carboxyl group which may be protected, and Y is a hydrogen atom, alkyl group, or a hydroxyl or carbonyl group which may be protected. Furthermore, novel compounds included in the 2-arylthiazole derivatives and pharmaceutically acceptable salts thereof are provided.
  
  Patent expiration dates:
  
  
  • March 25, 2014
    
    ✓ 
    Patent use: CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and method of producing the same
  Patent 6,225,474
  Issued: May 1, 2001
  Inventor(s): Matsumoto; Koichi & Watanabe; Kenzo & Hiramatsu; Toshiyuki & Kitamura; Mitsutaka
  Assignee(s): Teijin Limited
  The present invention provides a technique of selectively producing a desired polymorph of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid. The present invention also provides a method of producing various polymorphs of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, which comprises crystallizing under the conditions defined by a specific temperature and a composition of a mixed solvent of methanol and water, and polymorphs obtained by the method. The present invention further provides a method of producing the other polymorphs or amorphous compounds by drying a specific polymorph under a reduced pressure with heating, and the other polymorphs or amorphous compounds obtained by the method.
  
  Patent expiration dates:
  
  
  • June 18, 2019
    
    ✓ 
    Drug substance
  
  



• 
  Solid preparation containing single crystal form
  Patent 7,361,676
  Issued: April 22, 2008
  Inventor(s): Iwai; Michio & Nakamura; Kazuhiro & Dohi; Masahiko & Mochizuki; Hiroko & Mochizuki; Seiji
  Assignee(s): Teijin Limited
  There are provided a solid preparation containing a single crystal of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid, an excipient and a disintegrating agent, and a method for producing the same.
  
  Patent expiration dates:
  
  
  • March 8, 2024
    
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 13, 2014 - NEW CHEMICAL ENTITY
  
  

See also...

• Uloric Consumer Information (Drugs.com)
• Uloric Consumer Information (Wolters Kluwer)
• Uloric Consumer Information (Cerner Multum)
• Uloric Advanced Consumer Information (Micromedex)
• Uloric AHFS DI Monographs (ASHP)
• Febuxostat Consumer Information (Wolters Kluwer)
• Febuxostat Consumer Information (Cerner Multum)
• Febuxostat Advanced Consumer Information (Micromedex)
• Febuxostat AHFS DI Monographs (ASHP)